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THE DEVELOPMENT OF A CANDIDATE TUBERCULOSIS DNA VACCINE 
EXPRESSING Mtb8.4 and Ag85B of Mycobacterium tuberculosis  
 
 
ABSTRACT 
 
 
Tuberculosis (TB) is still one of the major health problems worldwide. The only TB vaccine 
currently available is an attenuated strain of Mycobacterium bovis, bacille Calmette Guerin 
(BCG). However, the efficacy of BCG vaccine continues to be debated. Therefore, a more 
effective vaccine against TB is urgently needed. DNA vaccination is a new approach to the 
control of infectious agents. In this study, a DNA vaccine encoding the candidate TB 
antigens Mtb8.4 and Ag85B was developed using assembly PCR. Balb/c mice were 
immunized intramuscularly with 50 μg of the DNA vaccine, pNMN023, containing the two 
antigens, in each hindleg. Reactivity against the Ag85B peptides, P1 and P3 as well as  
Mtb8.4 showed a consistent Th1 type of immune response by virtue of the increased 
expression of IL-2, IFN-γ and IgG2a. Splenocytes from immunized mice were also found to 
proliferate more aggressively when stimulated with the antigens compared to the vector 
alone. In order to improve the vaccine efficacy, a preliminary prime-boost approach was 
used. Priming with pNMN023 and boosting with recombinant BCG (rBCG) in Balb/c mice 
was carried out. Flow cytometric intracellular cytokine analyses of splenocytes from mice 
immunized with the DNA-rBCG prime-boost regime showed that both CD4+ and CD8+ T 
cells showed an increase in IL-2 and IFN-γ production following stimulation with either 
antigens at significantly higher levels than those immunized with rBCG-DNA prime-boost. 
In conclusion, the data obtained from this study suggest that DNA vaccination in 
combination with the prime-boost approach provide a potential strategy for developing a 
candidate vaccine against TB.  
 
 
PEMBANGUNAN CALON DNA VAKSIN TERHADAP TUBERKULOSIS YANG 
MENGEKSPRESKAN  Mtb8.4 DAN Ag85B DARIPADA  
Mycobacterium tuberculosis  
 
ABSTRAK  
 
Tuberkulosis (TB) merupakan salah satu penyakit utama di dunia. Satu-satunya vaksin TB 
yang terdapat pada masa ini ialah strain yang telah dilemahkan iaitu, Mycobacterium bovis 
bacille Calmette-Guerin (BCG). Bagaimanapun, keberkesanan BCG masih diperdebatkan. 
Oleh itu, vaksin yang lebih efektif terhadap TB sangat diperlukan. Vaksin DNA merupakan 
salah satu cara untuk mengawal ejen infeksi. Di dalam kajian ini, vaksin DNA yang 
mengkodkan antigen TB iaitu, antigen Mtb8.4 dan antigen Ag85B telah dibangunkan 
menggunakan kaedah PCR himpunan. Mencit Balb/c telah diimunisasi intraotot dengan 50 
μg vaksin DNA, pNMN023, yang mengandungi kedua-dua antigen. Kereaktifan terhadap 
peptida Ag85B, P1 dan P3 juga Mtb8.4 telah menunjukkan peningkatan tindakbalas imun 
jenis Th1 yang konsisten melalui peningkatan pengekspresian IL-2, IFN-γ dan IgG2a. 
Splenosit dari mencit yang diimunisasi juga didapati menunjukkan peningkatan gerak 
balas proliferasi apabila dirangsang dengan kedua-dua antigen. Untuk meningkatkan 
keberkesanan vaksin, kajian awal menggunakan pendekatan ‘prime-boost’ telah 
digunakan. ‘Priming’ dengan pNMN023 dan ‘boosting’ dengan BCG rekombinan (rBCG) di 
dalam mencit Balb/c telah dijalankan. Analisis intrasel sitokin dari splenosit mencit yang 
telah diimunisasi dengan DNA-rBCG menunjukkan peningkatan IL-2 dan IFN-γ kedua-dua 
sel T CD4+ dan CD8+ apabila dirangsang dengan kedua-dua antigen berbanding mencit 
yang diimunisasi dengan rBCG-DNA. Sebagai kesimpulan, data yang diperolehi dari kajian 
ini mencadangkan bahawa vaksin DNA digabungkan dengan kaedah ‘prime-boost’ 
merupakan salah satu kaedah yang berpotensi untuk membangunkan calon vaksin 
terhadap TB.     
 
 
CHAPTER 1 
 
LITERATURE REVIEW  
 
 
1.1 History of tuberculosis   
Tuberculosis (TB) in humans is caused by Mycobacterium tuberculosis while M. 
bovis causes TB infection in cattle. The Hippocratic Collection compiled around 400 - 350 
B.C. recorded the clinical manifestations and epidemiologic features of phthisis (Greek 
term), the tuberculous process in the lungs was called a ‘phyma’ (Iseman, 2000). The 
frequency of unearthed skeletons with apparent tubercular deformities in ancient Egypt 
suggests that the disease was common among that population. Evidence of bone lesions 
suggestive of TB in mummies of North America and Egypt confirms the ancient impact of 
this disease on early civilizations (Nerlich et al., 2000; Rothschild et al., 2001) and further 
confirmed by the use of molecular-based diagnosis of TB in some ancient Egyption 
mummies (reviewed by Bedeir, 2004). 
 
During the golden age of Islam, Ibnu Sina described the clinical features and pathology of 
TB in Arabic scripts (reviewed by Madkour et al., 2004). The discovery of similarly 
deformed bones in various Neolithic sites in Italy, Denmark, and countries in the Middle 
East also indicates that TB was found throughout the world approximately 4,000 years 
ago. 
   
In the 18th century, TB was well established in Europe and had spread to Africa, Asia, 
South America and Eastern Europe by the end of the 19th century. In 1882, Robert Koch 
discovered tubercle bacillus as the causative agent of TB. In 1993, due to the emergence 
of TB incidence worldwide, TB was declared as a ‘global emergency’ by the World Health 
Organization (WHO) and a decade later, the first international conference on ‘TB vaccine 
for the world’ was held in Montreal. 
 
1.2 Disease burden  
It is estimated that two billion people (one third of the world’s population) is infected 
with M. tuberculosis (WHO, 2001), where 8.8 million people will show clinical diseases and 
1.5 million will die every year (WHO, 2004). TB also occurs in Southeast Asia with three 
million new cases every year and a quarter of a million in Eastern Europe (Girard et al., 
2005). These situations are worsened with the estimation that only 40% of new cases of 
pulmonary TB are currently detected (Dye et al., 2002). If controlling efforts are not 
accelerated, 10 million new TB cases are expected in 2010 (Dye, 2000).  
 
Rising rates of drug-resistant TB have contributed to worsen treatment outcomes in some 
regions (Figure 1.1). The incidence of TB increased in areas with high rates of human 
immunodeficiency virus (HIV) infection. Approximately, 14 million people are co-infected 
with M. tuberculosis and HIV, including more than 70% of those living in some regions of 
sub-Saharan Africa (WHO, 2004).  
  
An initiative to address the increase of TB disease burden known as “Stop TB” was 
created in 1998 to ensure that endemic countries are adequately supported by technically 
and financially to control TB (Raviglione & Pio, 2002). Among the supports include the US 
National Institute for Allergy and Infectious Diseases (NIAID), the Aeras Global TB Vaccine 
Foundation, the European Union Commission and pharmaceutical manufacturers including 
GlaxoSmithKline (GSK) and IDRI-Corixa (Hewinson, 2005).   
 
 
  
 
Figure 1.1: Tuberculosis notification rates, 2004. (Adapted from WHO report 2006)  
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1.3 Mycobacterium tuberculosis infection 
M. tuberculosis belongs to the Mycobacteriaceae family and Actinomycetales 
order. Humans are the only reservoirs. M. tuberculosis is an aerobic, non-spore forming, 
non-motile, slightly curved or straight rod bacterium of 0.2 - 0.6 X 1.0 - 10 µm in length. 
The cell wall of M. tuberculosis contains high content of complex lipids. One of the 
components is mycolyl-arabinogalactan which acts as a hydrophobic permeability barrier 
that prevents penetration of common aniline dyes. 
TB is spread through the air from one person to another. Primary infection begins upon 
inhalation of 1-10 aerosolized bacilli. The bacteria can settle in the lungs and begin to 
grow. From there, they can move through the blood to other parts of the body, such as the 
kidney, spine, and brain. This pathogenic mycobacteria can survive in the hostile habitat of 
the macrophage, the main immune cell that attract the bacilli. Following the infection of M. 
tuberculosis, 30% of individuals will become infected, with about 40% of these individuals 
develop primary active TB while the remaining 60% develop latent infection (Figure 1.2). 
Latent infection is described as a clinical syndrome that occurs after an individual has been 
exposed to M. tuberculosis. During that particular stage, the immune response has been 
generated to control the pathogen and force it into a dormant stage. Individuals with latent 
TB do not transmit the disease. After years of dormancy, this organism may start to 
replicate, leading to reactivation of infection and clinical disease. Individual who is latently 
infected, can develop active disease via either endogenous reactivation of the latent bacilli 
or exogenous reinfection with a second mycobacterial strain. Approximately, 2 - 23% of 
immunocompetent patients with latent TB will reactivate at a later date, while patients with 
HIV develop reactivation of TB at a rate of 5 - 10% per year (Figure 1.2) due to progressive 
depletion and dysfunction of the macrophage (Goletti et al., 1996).  
 
 
  
                                 
 
 
 
 
 
  Figure 1.2: Outcomes associated with exposure to M. tuberculosis. (Adapted from Parrish et al., 1998). 
 
 
 
 
 
 
 
The capacity to limit the proliferation of tubercle bacilli within macrophage resides largely 
with CD4+ T-helper (Th) lymphocytes. Despite HIV patients, the reactivation of the 
pathogen will most probably occur in people with immunosuppression due to age, 
corticosteroids and malnutrition (Flynn, 2004).  
The pathogenicity of the organism is determined by its ability to escape the host immune 
response as well as eliciting delayed type hypersensitivity (DTH). DTH is used as a 
general category to describe all those hypersensitivity reactions that take more than 12 
hours to develop, which involve cell-mediated immune (CMI) reactions rather than humoral 
immune reactions. DTH skin testing or Mantoux reaction is carried out to determine 
previous exposure to TB by injection of tuberculin into the skin of an individual in whom 
previous infection with the mycobacterium had induced a state of CMI. The reaction is 
characterized by erythema and induration which appears only after several hours and 
reaches a maximum at 24 - 48 hours. 
 
1.4         Diagnosis  
The most common method used to diagnose TB is by smear microscopy or known as 
Acid-fast bacillus (AFB) shown in Figure 1.3 which is the most popular, rapid and 
inexpensive method. However, the reliability of this method is highly dependent on the 
experience of the laboratory personnel and on the number of organisms present in the 
specimen. Another method known as the current ‘gold standard’ is by culture whether on 
solid or liquid media.  
 
One of the latest technologies used to diagnose TB is by nucleic acid amplification (NAA)-
based assays. NAA refers to a technique in which the nucleic acid (DNA or RNA) of an  
 
     
       
        
Figure 1.3: AFB smear  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AFB (shown in red) are 
tubercle bacilli) 
organism is amplified by as much as 40 orders of magnitude, after which a probe detects a 
target sequence of DNA or RNA unique to a particular organism. Compared to smear and 
culture technique, sensitivity and specificity of NAA are usually very high (Pfyffer, 1999) 
and can detect as few as 10 organisms in 1 ml of clinical sample (Schluger & Rom, 1995). 
NAA method can also reduce the diagnostic time from weeks to days. Currently, two NAA 
methods are available commercially, the Enhanced Mycobacterium tuberculosis Direct 
Test (Gen-Probe®) and the Amplicor® Mycobacterium tuberculosis Test (Roche Diagnostic 
Systems) (reviewed by Soini & Musser, 2001). Both products have been approved by the 
Food and Drug Administration USA (FDA) in 1999 for direct detection of M. tuberculosis 
from clinical specimens (CDC, 2000). The NAA test can enhance diagnostic speed, but 
could not replace AFB smear or culture because the test cannot distinguish between live 
and dead organisms. In addition, NAA test require complex equipment as well as highly 
technical staff. Therefore, clinicians should interpret the NAA test results based on the 
clinical situation and the test should be performed at the request of the clinician (Soini & 
Musser, 2001).   
 
Besides the AFB, culture and NAA methods of TB diagnosis, susceptibility testing is one of 
the available alternatives if the culture remains positive over a longer period of time. Drug 
susceptibility testing is mandatory on initial isolates of M. tuberculosis and related species 
from all patients. Susceptibility testing is conducted to monitor a possible development of 
drug resistance. Conventional method for drug susceptibility is by testing on solid media 
(Middlebrook 7H11 or LJ). Another recent method of drug susceptibility testing is by 
radiometric liquid culture system (BACTEC) which provides a vial containing a substance 
[para-nitro-alpha-acatylamine-hydroxypropiophenone (NAP)], which selectively suppress 
the growth of M. tuberculosis complex species. Among members of the M. tuberculosis 
complex are M. tuberculosis, M. bovis, M. africanum and M. microtii. Each member of the 
M. tuberculosis complex is pathogenic. If a subculture from the initial vial fails to 
demonstrate growth in the NAP, that is presumptive evidence for a species within M. 
tuberculosis complex.  
 
1.5        Symptoms and treatments  
The symptoms of TB depend on the site where the bacteria are growing whether in 
pulmonary or extrapulmonary. In the lungs, symptoms such as coughing for 3 weeks or 
longer, pain in the chest and coughing out blood or sputum are very common. Only active 
TB patients will show some other possible symptoms which are; weakness or fatigue, 
weight loss, fever, sweating at night and reduced appetite. Besides pulmonary TB, most 
extrapulmonary forms of TB includes; TB meningitis, tuberculous lymphadenitis, pericardial 
TB, pleural TB and disseminated or miliary TB. People with HIV, infants and young 
children seem to have an increased risk for extrapulmonary TB.  
  
Containment of TB has been carried out by the WHO-recommended “directly observed 
treatment short course” (DOTS) strategy. This treatment involves TB patients observed 
taking every single dose drug for the first 2 month of the 6 to 8 month treatment regimens. 
More than 17 million patients benefited from the DOTS strategy, but in some cases multi-
drug resistant TB (MDR-TB) occurs when the treatment is incomplete (Girard et al., 2005). 
MDR-TB is defined as strains of M. tuberculosis resistant to at least isoniazid and 
rifampicin, the two most powerful anti-TB drugs. The first documented case of MDR-TB 
was in a lung transplant patient in 1999 (Lee et al., 2003). Transplant patients are 
chronically immunosuppressed and in that study, the donated lungs were from a recent 
Chinese immigrant who was at high-risk for previous exposure. Fortunately, fluctuations 
and variations of isoniazid, rifampicin, pyrazinamide and rifabutin were successful in 
saving the patient.   
1.6     Immune response against TB 
Immune response involved in TB infection is complex. The components involved are T 
cells (CD4+ and CD8+), cytokines (IFN-γ, TNF-α, IL-12 and IL-6) and macrophages (Flynn, 
2004). The immune response may also differ in acute and chronic infection. Four stages of 
pulmonary TB (Figure 1.4) have been reviewed by van Crevel et al. (2002). The first stage 
is the inhalation of tubercle bacilli. After an incubation period of 4 to 12 weeks, alveolar 
macrophage will ingest the bacilli and destroy them. These depend on the intrinsic 
microbicidal capacity of host phagocytes as well as the virulence factors of the ingested 
mycobacteria.  
 
Mycobacteria which escape the first stage will enter the second stage where three 
scenarios could occur. The first scenario is when the host failed to contain the pathogen 
and die. Secondly, the mycobacteria may spread throughout the body when the host 
immune response is weak (normally occurs in immunocompromised patients) causing 
active disease. The third scenario is when the host immune response and the virulence of 
M. tuberculosis are balanced and the intracellular bacteria are contained within the 
macrophage. Macrophage disruption will attract blood monocytes and other inflammatory 
cells to the lungs. Monocytes will differentiate into macrophages and ingest the 
mycobacteria but will not destroy them. Little tissue damage occurs at this stage. T cell 
immunity will develop after 2 to 3 weeks of infection, leading to proliferation of antigen 
specific T lymphocytes within the early lesions. Host immune system isolates the primary 
site of infection by granuloma formation. The granuloma contains lymphocytes including 
CD4+ and CD8+ T cells as well as B cells. In addition, fibroblasts and other cells can be 
present within the granuloma (Co et al., 2004). The granuloma functions to limit the spread  
 
 
 
  
 
Figure 1.4: Four stages of pulmonary TB (Modified from Kaufmann & Ulrichs, 2003) 
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of the infection by walling off the organisms from the rest of the lung, prevents metastasis 
of the infection and providing an environment for the action of the immune components 
(Salgame, 2005).  
 
During the third stage of pulmonary infection, the early bacilli growth will stop (Ulrichs & 
Kaufmann, 2003). Solid necrosis in the primary lesions will inhibit extracellular growth of 
mycobacteria and the infection may become dormant for months or years. During the final 
stage, any disturbance of the balance between the host and pathogen after weakening of 
the cellular immune response causes endogenous exacerbation which leads to active TB. 
Cavity formation may lead to rupture of nearby bronchi, causing the bacilli to spread to 
other parts of the lungs or host’s organ.  
 
1.6.1       Macrophage 
Macrophage has been identified as the key immune cell for the control of M. 
tuberculosis infection. The organism can multiply within resting macrophage but become 
inhibited when the macrophage is activated. Cytokines including IFN-γ and TNF-α and also 
vitamin D involves in macrophage activation (van Crevel et al., 2002). Following inhalation 
of mycobacteria droplets, M. tuberculosis is engulfed by alveolar macrophages. The 
interaction between macrophages and mycobacteria involves a variety of host cell 
receptors including Fc receptors (FcR), complement receptors (CR), macrophage 
mannose receptor (MMR) and also Toll-like receptor 2 (TLR-2) and TLR-4. 
 
 Macrophage plays multiple roles in TB including antigen processing and presentation, 
effector cell function and also apoptosis (Silva et al., 2001). Apoptosis of phagocytic cells 
may prevent dissemination of infection and reduces viability of intracellular mycobacteria. 
Klinger and colleagues (1997) have demonstrated that apoptosis associated with TB is 
mediated through a downregulation of bcl-2, an inhibitor of programmed cell death. The 
activated macrophage produces reactive oxygen intermediates (ROIs) by oxidative burst 
and reactive nitrogen intermediates (RNIs) via inducible nitric oxide synthase (iNOS2).  
Cooper et al. (2000) provided evidence that ROI-mediated control is important during early 
infection by the observation of a 10-fold higher bacterial numbers in the lungs of p47phox 
knockout (KO) mice, compared to wild-type controls, after aerosol challenge with M. 
tuberculosis. The p47phox is a phagosome oxidase component critical for the activity or 
assembly of the functional oxidase. RNIs are the critical effector molecules against M. 
tuberculosis in the mouse. Moreover, mice deficient in NOS2 activity are very susceptible 
to acute or chronic M. tuberculosis infection compared to wild-type mice (MacMicking et 
al., 1997; Scanga et al., 2001).  
 
Macrophage activation also involves natural-resistance-associated macrophage protein 
(Nramp1) gene and vitamin D. Nramp1 is an interesting gene involved in macrophage 
activation and mycobacterial killing (Blackwell et al., 2000). The protein is an integral 
membrane protein which belongs to a family of metal ion transporters. These metal ions, 
particularly Fe2+, are involved in macrophage activation and generation of toxic 
antimicrobial radicals (Zwilling et al., 1999). Following phagocytosis, Nramp1 becomes part 
of the phagosome. Nramp1 mutant mice display reduced phagosomal maturation and 
acidification (Hackam et al., 1998).  
 
Macrophage suppresses the growth of M. tuberculosis by the helps of active metabolite of 
vitamin D, 1, 25-dihydroxyvitamin D (Rockett et al., 1998). A recent study among Gujarati 
Hindus, a mainly vegetarian immigrant population in London, showed that vitamin D 
deficiency was a risk factor for TB (Wilkinson et al., 2000). Eventhough activated 
macrophage can sometimes kill virulent M. tuberculosis (Sato et al., 1998) but it is 
generally cannot eliminate the infection entirely. Therefore, other components of the 
immune system including cellular and humoral immune responses participate to eliminate 
the mycobacteria.  
 
1.6.2      Cellular Immune Response 
Van Crevel et al. (2002) has discussed three processes that contribute to the 
initiation of cellular immune response against TB; antigen presentation, costimulation and 
cytokine production. Antigen presentation involves CD4+ T cells, CD8+ T cells and 
unconventional T cells including CD1 and γδ T cells. In general, CD4+ T cells help to 
amplify the host immune response by activating effector cells and recruiting additional 
immune cells to the site of disease, whereas CD8+ T cells are important during the latent 
stage of TB infection, which act as cytotoxic T cells (CTL) by lysing infected cells (Schluger 
& Rom, 1998) through production of various cytokines such as IFN-γ and TNF-α. Within a 
week of infection with virulent M. tuberculosis, the number of activated CD4+ and CD8+ T 
cells in the lung-draining lymph nodes increases (Feng et al., 1999; Serbina et al., 2000).  
 
Basically, CD4+ Th lymphocytes differentiate from precursor Th0 cells under the control of 
cytokines such as IL-2 and IL-4 into two functionally distinct subsets either type 1 (Th1) or 
type 2 (Th2) cells (Figure 1.5). Th1 secretes cytokines such as IL-2, IFN-γ, TNF-α and IL-
12 resulting in macrophage activation and induction of CMI. In contrast, Th2 secretes IL-4, 
IL-5, IL-6 and IL-10 resulting in the induction of humoral immunity by antibody production. 
M. tuberculosis resides primarily in a vacuole within the macrophage resulting in major 
histocompatibility complex (MHC) Class II presentation of mycobacterial antigens to CD4+ 
T cells. The HIV epidemic has demonstrated that the loss of CD4+ T cells greatly increases 
susceptibility of the host to both acute and reactivation TB (reviewed by Flynn, 2004).  
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Figure 1.5: CD4+ T helper lymphocyte subsets upon activation. (Adapted from Cohen et 
al., 1998).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The other possible roles of CD4+ T cells in controlling TB infection include, apoptosis 
(Keane et al., 1997; Balcwicz-Sablinska et al., 1998), conditioning of antigen presenting 
cells (APCs), help for B cells and CD8+ T cells and production of other cytokines. However, 
the inability of the CD4+ T cells to completely eliminate intracellular bacteria may be due to 
the lack of recognition or activation of infected macrophages (Flynn, 2004).  
 
CD8+ T cells producing IFN-γ probably participate in the activation of macrophages 
(Caruso et. al., 1999; Scanga et al., 2000). CD8+ T cells recognize antigens presented by 
MHC Class I molecules and these antigens are frequently derived from the cytoplasm of 
the cells. However, M. tuberculosis does not reside primarily in the cytoplasm but in 
vacuoles inside the cells. Studies have suggested that the bacilli within the vacuoles may 
have access to the cytoplasm, perhaps via a pore in the vacuole’s membrane (Teitelbaum 
et al., 1999). It was suggested that CTL killing of the bacteria depends on their ability to 
deliver potent bactericidal proteins such as granulysin from their granules (Silva et al., 
2001). Lysis of target cells by CD8+ T cells can occur via perforin and granzymes or the 
Fas/FasL (CD95L) pathway resulting in apoptotic cell death or release of bacteria from an 
infected cell into the granuloma (Canaday et al., 2001).  The importance of CD8+ T cells in 
TB was reported by Behar et al. (1999), when β2-microglobulin (β2-m) and transporter 
associated protein (TAP1) KO mice, which cannot generate CD8+ T cells, were infected 
with M. tuberculosis and resulted in an exacerbated course of infection.  
 
As mentioned earlier, unconventional T cells such as CD1 and γδ T cells also play a role in 
host defense against mycobacterial infection. Both cells produce type 1 cytokines, most 
importantly IFN-γ which activates anti-mycobacterial activities in macrophages (Raupach & 
Kaufmann, 2001). CD1-restricted αβ T-lymphocytes are thought to be activated by 
mycobacterial lipids (Agger & Andersen, 2002). The CD1 family consists of antigen-
presenting molecules encoded by genes located outside of the MHC. CD1 genes are 
conserved among mammalian species and are expressed on the surface of the cells 
involved in antigen presentation, notably dendritic cells (DCs). The CD1 system is involved 
in activation of CMI response against mycobacterial infection. It is the least common T cell 
subset in human peripheral blood and lung. In humans, most of these T cells express 
neither CD4 nor CD8 and are referred to as double-negative (DN) cells. In mice, CD1d-
restricted natural killer (NK) T cells are activated by mycobacterial cell wall components 
and are involved in early granuloma formation (Apostolou et al., 1999).  
 
Meanwhile, γδ T cells are large granular lymphocytes, non-MHC restricted that can 
develop a dendritic morphology in lymphoid tissues and function as CTL. Unconventional 
γδ T cells are activated by small phosphorylated metabolites (Agger & Andersen, 2002). It 
was suggested that γδ T cells may play a role in early immune response against TB and is 
an important part of the protective immunity in patients with latent infection (reviewed by 
Raja, 2004).  
 
The second process that leads to the initiation of cellular immunity is by costimulation. 
Antigen presentation only leads to T cell stimulation in the presence of several 
costimulatory signals. The most well known costimulatory signals for T cell stimulation are 
B-7.1 (CD80) and B-7.2 (CD86). These molecules are expressed on macrophages and 
DCs and bind to CD28 and to CTLA-4 on T cells. In the absence of proper costimulatory 
signals, antigen presentation may lead to an increased apoptosis of T cells (Hirsch et al., 
1999 & 2001).  
 
Finally, the production of cytokines may also contribute to the initiation of cellular immunity 
in TB infection. Several cytokines produced by activated macrophages and DCs are 
essential for stimulation of T lymphocytes. These include IFN-γ, TNF-α, IL-4, IL-12, IL-18 
and IL-15. IFN-γ is produced by T cells from healthy purified protein derivative positive 
(PPD+) subjects as well as those with active TB. IFN-γ is important to activate macrophage 
as well as TNF-α that synergize with IFN-γ to induce antimycobacterial effects. Individuals 
lacking receptors for IFN-γ suffer from recurrent, sometimes lethal mycobacterial infections 
(Holland et al., 1998). There are three possible cells responsible for nonspecific production 
of IFN-γ as reviewed by van Crevel et al. (2002). First, before adaptive T cell immunity has 
fully developed, NK cells may be the main producer of IFN-γ, either in response to IL-12 
and IL-18 (Iho et al., 1999) or directly by exposure to mycobacterial oligodeoxynucleotides 
(Garcia et al., 1999). Second, lung macrophages were found to produce IFN-γ in M. 
tuberculosis-infected mice (Wang et al., 1999). Third, the γδ T cells and CD1-restricted T 
cells may produce IFN-γ during early infection.  
 
Besides IFN-γ, stimulation of monocytes, macrophages and DCs (Henderson et al., 1997) 
with mycobacteria or mycobacterial products induce the production of TNF-α. TNF-α plays 
a role in granuloma formation, induces macrophage activation and has immunoregulatory 
properties (Orme & Cooper, 1999; Tsenova et al., 1999). In addition to TNF-α, IL-12 has a 
crucial role in the induction of IFN-γ production (O’Neill & Greene, 1998). IL-12 is produced 
mainly by phagocytic cells. In TB, IL-12 has been detected in lung infiltrates, in pleurisy, in 
granulomas and in lymphadenitis (reviewed by van Crevel et al., 2002). The expression of 
IL-12 receptors is also increased at the site of disease (Zhang et al., 1999). Together with 
IL-12, IL-18 and IL-15 seem to be important in the IFN-γ axis (O’Neill & Greene, 1998). IL-
18 KO mice was found to be highly susceptible to M. tuberculosis (Sugawara et al., 1999) 
and in mice infected with M. leprae, resistance is correlated with a higher expression of IL-
18. Moreover, M. tuberculosis-mediated production of IL-18 by peripheral blood 
mononuclear cells (PBMC) is reduced in TB patients and this reduction may be 
responsible for reduced IFN-γ production (Vankayalapati et al., 2000).  
 
Another cytokine that have been studied regarding TB infection is IL-4. Inhibition of IL-4 
production did not seem to promote cellular immunity. IL-4-/- mice displayed normal 
instead of increased susceptibility to mycobacteria in two studies, suggesting that IL-4 may 
be a consequence rather than the cause of TB development (Erb et al., 1998; North, 
1998).  
 
1.6.3      Humoral Immune Response 
Researchers argued about the role of antibodies in host defense against M. 
tuberculosis which was believed that intracellular pathogens cannot be reached by 
antibodies. However, intracellular pathogens are found in the extracellular space prior to 
their entry into cells. Furthermore, certain antibodies can enter or mediate biological effects 
inside cells (reviewed by Glatman-Freedman & Casadevall, 1998). Previous work 
demonstrated protective effects of antibodies against infection with the intracellular fungus 
Cryptococcus neoformans, as well as other intracellular pathogens (reviewed by 
Casadevall, 1998). Recently, there are several studies that support the role of antibodies in 
M. tuberculosis infection (Bosio et al., 2000).  
 
M. tuberculosis will infect pulmonary lymph nodes and other organs such as spleen and 
liver. The dissemination of M. tuberculosis probably occurs via entry into alveolar 
macrophages and via interaction with epithelial cells (Pethe et al., 2001). Heparin binding 
hemagglutinin adhesion (HBHA) is a surface-exposed glycoprotein involved in the binding 
of M. tuberculosis to epithelial cells. Administration of M. bovis coated with anti-HBHA 
monoclonal antibodies (mAbs) intranasally reduced colony forming unit (CFU) in the 
spleen (Pethe et al., 2001) suggesting that anti-HBHA antibodies interfered with 
mycobacterial dissemination.  
 
Despite playing a role in mycobacterial dissemination, humoral immune response also 
involved in cytokine expression. A study on the effect of antibodies to PPD on TNF-α 
expression by monocytes was carried out by Hussain et al. (2000). TNF-α is a pro-
inflammatory cytokine involved in host response against M. tuberculosis, as well as the 
immunopathology of TB (Engele et al., 2002). TNF-α secretion by PPD-stimulated 
monocytes from PPD skin test-negative donors was enhanced in the presence of heat-
inactivated plasma obtained from patients with pulmonary TB (Hussain et al., 2000). 
Furthermore, TNF-α secretion directly correlated with plasma concentration of IgG1 to 
PPD and adsorption of IgG1 from plasma samples led to reduction of TNF-α secretion 
suggesting a potential role for certain antibody in mediating a biological effect via cytokine 
release.  
 
Mycobacteria enter the host via the mucosa, therefore antibodies in the secretions could 
play a role in host defense against mycobacteria. In another study, high titers of antibodies 
against mycobacteria were observed in mice administered with human gammaglobulin 
formation and challenged after 2 hours by the intranasal route (Acosta et al., 2003). In 
addition, mice lungs showed significantly decreased CFU 24 hours after the challenge.    
 
 
 
1.7 BCG – the current vaccine  
The bacille Calmette-Guerin (BCG) vaccine was named after the French scientists 
Calmette and Guerin in 1908. They isolated M. bovis from a cow with tuberculous mastitis 
(a common symptom in cattle with bovine TB). They cultured this isolate in a glycerinated, 
beef/bile/potato medium, subculturing every three weeks for a total of 231 passages, over 
a period of 13 years. The so-called BCG Pasteur strain was widely distributed throughout 
the world. As a result, many daughter substrains developed and numerous changes, gene 
deletions as well as continued passage have attenuated BCG to almost complete 
avirulence (Behr et al., 1999a; Sabino et al., 2004). A review by Brosch et al. (2001), found 
that there are at least 18 variable regions of difference (RD), representing 120 genes 
present in M. tuberculosis H37Rv but absent in BCG Pasteur. One region, RD1, is missing 
in all BCG strains but is present in all M. bovis and M. tuberculosis strain (Mahairas, 1996; 
Cole et al., 1998; Behr et al., 1999b; Brosch, 2000). This RD1 region might contain some 
of the genes involved in virulence or regulators of virulence genes. These might account 
for the phenotypic differences between the vaccine strain and M. tuberculosis.  
 
BCG was first tested in infants in 1921 as an oral vaccine. New methods of administration 
were introduced later, such as intradermal, multiple puncture and scarification. The most 
widely used BCG vaccine substrains include Connaught, Danish, Glaxo, Moreau, Pasteur 
and Tokyo (Oettinger et al., 1999). In 1974, BCG vaccination has been included in the 
WHO Expanded Program on Immunization, resulting in more than three billion doses 
injected worldwide and approximately 100 million immunizations in children each year. 
BCG is routinely administered to newborns in countries where TB is endemic and in some 
lower-incidence countries. A common minor side effect of BCG immunization is the 
production of induration and ulceration at the vaccination site.  
 
